Kilitch Drugs Peer Comparison

NSE: KILITCH | BSE: 524500

₹244.09

₹-12.16 (-4.75%)

As on 08-Oct-2026 15:24IST

Market cap

₹853 Cr

Revenue (TTM)

₹237 Cr

P/E Ratio

28.4

P/B Ratio

Div. Yield

0 %

Edit

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	853	20,061	19,562	17,133	16,303
Revenue (₹ Cr)	237	1,682	2,287	2,570	3,230
Net Profit (₹ Cr)	29.20	273.51	678.07	735.15	666.92
Net Margin (%)	11.74	16.19	28.10	26.88	20.60
RoE (%)	11.02	11.15	19.73	19.16	18.75
Price to Earnings	28.38	67.47	29.40	23.31	25.32
Price-To-Book	3.03	7.47	5.33	3.89	4.04

Income Statement (₹ Cr)

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	237.21	1,682.47	2,287.33	2,569.77	3,229.67
Total Income	248.79	1,689.83	2,413.29	2,735.39	3,237.12
Total Expenditure	200.94	1,203.91	1,490.75	1,628.14	2,090.06
EBITDA	36.27	478.55	796.58	941.63	1,139.61
Depreciation	3.87	126.01	78.10	57.58	281.06
EBIT	32.40	352.55	718.48	884.05	858.55
Interest	4.91	52.11	0.88	7.69	190.64
Other Income	11.58	7.37	125.96	165.62	7.45
Exceptional Items	0.00	12.16	0.00	-49.16	-17.24
Profit before Tax	39.07	319.96	843.56	992.82	658.12
Provision for Tax	9.86	46.45	165.49	257.67	-8.80
Profit after Tax	29.20	273.51	678.07	735.15	666.92

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	279.65	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	0.85	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	59.28	266.35	28.74	91.50	1,392.75
Current Liabilities	121.60	848.06	385.94	627.48	2,077.10
Total Liabilities	457.75	3,705.61	4,037.51	4,921.88	7,246.72

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	235.55	2,525.44	1,291.22	770.28	5,617.77
Current Assets	222.20	1,109.77	2,585.66	3,803.22	1,539.85
Total Assets	457.75	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	88.71	657.97	0.57	2.50	2,309.68
Net Current Assets	100.60	261.71	2,199.72	3,175.74	-537.25
Contingent Liabilities	0.76	160.01	17.53	370.49	51.57

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	23.96	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-100.44	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	82.45	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	5.97	29.88	-105.52	-392.41	-145.00

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	14.50	11.43	24.97	23.39	14.47
ROE (%)	11.02	11.15	19.73	19.16	18.75
ROA (%)	7.58	7.80	18.69	14.95	9.26
EBIT Margin (%)	13.66	20.95	31.41	34.40	26.58
Net Margin (%)	11.74	16.19	28.10	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	14.04	27.91	15.01	10.69	9.59
EBIT Growth (%)	9.51	58.32	18.45	24.14	16.84
Net Profit Growth (%)	9.37	149.56	19.61	-9.09	62.68
EPS Growth (%)	-29.89	-3.57	17.73	14.40	67.41
Book Value Growth (%)	38.28	9.67	26.75	-0.34	36.71

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	20.99	74.81	30.29	22.63	24.09
Price / Book Value	3.18	7.81	5.49	3.96	3.95
Dividend Yield (%)	0.00	0.06	0.30	1.97	0.00
EV/EBITDA	25.24	45.10	24.03	15.24	15.93
Market Cap (₹ Cr)	445.94	6,819.66	11,439.22	21,592.90	17,980.08

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.21	0.07	0.00	0.00	0.24
Short term debt to equity ratio	0.11	0.16	0.00	0.00	0.12
Current Ratio	1.83	1.31	6.70	6.06	0.74
Quick Ratio	1.73	0.88	5.59	5.31	0.53
Interest Coverage	8.96	7.14	959.59	130.11	4.45

	Kilitch Drugs	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	50.66	30.84	36.10	7.07	21.07
Asset Turnover	0.62	0.48	0.63	0.52	0.45
Receivable days	158.82	113.81	121.68	26.06	63.88
Inventory Days	20.79	84.76	63.83	65.95	43.27
Payable days	193.60	101.94	108.28	81.01	151.85
Cash Conversion Cycle	-13.99	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.